Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, with FUT8 knocked out, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.
Molekulargewicht:
232.23
Formel:
C13H12O4
Target-Kategorie:
EGFR
T9901A-232
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
